Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390)

被引:58
作者
Laskin, Janessa [1 ]
Crino, Lucio [2 ]
Felip, Enriqueta [3 ]
Franke, Fabio [4 ]
Gorbunova, Vera [5 ]
Groen, Harry [6 ]
Jiang, Guo-liang [7 ]
Reck, Martin [8 ]
Schneider, Claus-Peter [9 ]
机构
[1] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada
[2] Hosp S Maria della Misericordia, Dept Oncol, Perugia, Italy
[3] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[4] Hosp Caridade, Ijui, Brazil
[5] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia
[6] Univ Groningen, Univ Groningen Hosp, Dept Pulm Dis, Groningen, Netherlands
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
[8] Hosp Grosshandorf, Dept Thorac Oncol, Grosshansdorf, Germany
[9] Cent Clin Bad Berka, Dept Oncol, Bad Berka, Germany
关键词
Bevacizumab; Vascular endothelial growth factor; Safety; Elderly; Non-small cell lung cancer (NSCLC); PHASE-III TRIAL; SINGLE-AGENT; PLATINUM COMBINATIONS; GERIATRIC ONCOLOGY; CISPLATIN; CARBOPLATIN; VINORELBINE; THERAPY; GEMCITABINE; PACLITAXEL;
D O I
10.1097/JTO.0b013e3182370e02
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Safety of Avastin in Lung (MO19390) was an international, open-label, single-arm study, which assessed the safety and efficacy of first-line bevacizumab (Avastin (R)) in combination with standard chemotherapy in patients (n = 2212) with advanced or recurrent non-small cell lung cancer (NSCLC). A preplanned subgroup analysis was performed to examine these outcomes in elderly patients older than 65 years. Methods: Eligible patients with nonsquamous NSCLC received up to six cycles of bevacizumab (7.5 or 15 mg/kg) plus any standard of care chemotherapy. Patients who did not experience disease progression after induction therapy continued bevacizumab therapy until disease progression or unacceptable toxicity. The primary end point was safety; secondary end points included time to disease progression (TTP) and overall survival (OS). Results: Data were evaluated for 623 patients older than 65 years (mean age 70.6). The majority were Whites (86.2%) with stage IV disease (79.7%) and had adenocarcinoma (83.5%). The incidence of adverse events (AEs) of special interest was similar for elderly and younger patients (any grade bleeding 38.2% versus 38.3%; any grade hypertension 33.1% versus 30.6%; any grade proteinuria 33.4% versus 29.3%). Most AEs were grade less than or equal to 2. Serious AEs were reported in 45.3 and 34.7% of elderly and younger patients, respectively. Median OS was similar in elderly and younger patients (14.6 months in both age groups), as were TTP (8.2 versus 7.6 months), response rate (49.3% versus 52.4%), and disease control rate (89.3% versus 88.4%). Similar results were seen in a post hoc comparison of the older than 70 years and 70 years or younger subgroups: TTP was 8.6 months versus 7.7 months, respectively; OS was 14.6 months in both subgroups; response rate was 49% and 52%, respectively; incidence of AEs of special interest was comparable. Conclusion: Patients older than 65 years with nonsquamous NSCLC derive a similar clinical benefit from first-line bevacizumabbased therapy as their younger counterparts and do not experience increased toxicity.
引用
收藏
页码:203 / 211
页数:9
相关论文
共 33 条
[1]  
[Anonymous], J CLIN ONCOL
[2]  
[Anonymous], NCCN Clinical Practice Guidelines in Oncology - Breast Cancer
[3]   Geriatric oncology: challenges for the new century [J].
Balducci, L .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) :1741-1754
[4]   Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326) [J].
Belani, CP ;
Fossella, F .
CANCER, 2005, 104 (12) :2766-2774
[5]   Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study [J].
Crino, Lucio ;
Dansin, Eric ;
Garrido, Pilar ;
Griesinger, Frank ;
Laskin, Janessa ;
Pavlakis, Nick ;
Stroiakovski, Daniel ;
Thatcher, Nick ;
Tsai, Chun-Ming ;
Wu, Yi-long ;
Zhou, Caicun .
LANCET ONCOLOGY, 2010, 11 (08) :733-740
[6]   Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up [J].
D'Addario, G. ;
Felip, E. .
ANNALS OF ONCOLOGY, 2008, 19 :39-40
[7]   Who gets chemotherapy for metastatic lung cancer? [J].
Earle, CC ;
Venditti, LN ;
Neumann, PJ ;
Gelber, RD ;
Weinstein, MC ;
Potosky, AL ;
Weeks, JC .
CHEST, 2000, 117 (05) :1239-1246
[8]   Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group [J].
Fossella, F ;
Pereira, JR ;
von Pawel, J ;
Pluzanska, A ;
Gorbounova, V ;
Kaukel, E ;
Mattson, KV ;
Ramlau, R ;
Szczesna, A ;
Fidias, P ;
Millward, M ;
Belani, CP .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3016-3024
[9]   Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial [J].
Gridelli, C ;
Perrone, F ;
Gallo, C ;
Cigolari, S ;
Rossi, A ;
Piantedosi, F ;
Barbera, S ;
Ferraù, F ;
Piazza, E ;
Rosetti, F ;
Clerici, M ;
Bertetto, O ;
Robbiati, SF ;
Frontini, L ;
Sacco, C ;
Castiglione, F ;
Favaretto, A ;
Novello, S ;
Migliorino, MR ;
Gasparini, G ;
Galetta, D ;
Iaffaioli, RV ;
Gebbia, V .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) :362-372
[10]   The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer [J].
Gridelli, C .
ONCOLOGIST, 2001, 6 :4-7